These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 28356598)
1. PARP inhibitors plough on. Mullard A Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598 [No Abstract] [Full Text] [Related]
2. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. Stewart J; George A; Banerjee S Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674 [TBL] [Abstract][Full Text] [Related]
3. Olaparib, a new hope for ovarian cancer. Samoon Z; Jabbar AA Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438 [No Abstract] [Full Text] [Related]
4. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085 [TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
7. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Liu JF; Matulonis UA Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274 [No Abstract] [Full Text] [Related]
9. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796 [TBL] [Abstract][Full Text] [Related]
10. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Sui H; Shi C; Yan Z; Li H Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641 [TBL] [Abstract][Full Text] [Related]
11. Olaparib (Lynparza) for advanced ovarian cancer. Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702 [No Abstract] [Full Text] [Related]
12. PARP inhibitors: targeting the right patients. Azvolinsky A J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976 [No Abstract] [Full Text] [Related]
13. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331 [TBL] [Abstract][Full Text] [Related]
14. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Matulonis UA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Parry D; Grinsted L; Ledermann JA Cancer; 2016 Jun; 122(12):1844-52. PubMed ID: 27062051 [TBL] [Abstract][Full Text] [Related]
15. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581 [TBL] [Abstract][Full Text] [Related]
16. Olaparib: first global approval. Deeks ED Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305 [TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307 [TBL] [Abstract][Full Text] [Related]
19. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer. Tewari KS; Eskander RN; Monk BJ Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965 [TBL] [Abstract][Full Text] [Related]
20. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]